HCA Healthcare, Inc. — Form 8-K

HCA Healthcare reported Q2 2026 revenues of $20.230B (+8.7% YoY) and net income of $1.699B (+2.8% YoY), with diluted EPS of $7.62 (+11.6% YoY). However, the company revised full-year 2026 guidance downward: revenues to $77.0–$79.5B (from $76.5–$80.0B), net income to $6.3–$6.7B (from $6.495–$7.035B), and adjusted EBITDA to $15.4–$16.1B (from $15.55–$16.45B). The deterioration reflects a ~$400M unfavorable payer mix shift due to uninsured volume increases from health insurance exchange coverage losses, partially offset by ~$400M net benefit from Florida Medicaid supplemental payment programs ($1.372B incremental revenues, $829M incremental expenses). Share repurchases totaled $2.064B for 4.752M shares; the company has $7.210B remaining authorization.